Treatment Landscape in ER+/HER2- Metastatic Breast Cancer and Unmet Needs

Holly Pederson, MD, and Elisha Hughes, MD, discussed the use of a polygenic risk score to identify why Black women incur higher rates of triple-negative breast cancer at younger ages.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

During a Case-Based Roundtable® event, Aditya Bardia, MD, MS, FASCO discussed recent updates from the DestinyBreast03 trial and other key data on treatment for HER2+ breast cancer in the first article of a 2-part series.

In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.

For Breast Cancer Awareness Month, Deborah Toppmeyer, MD, emphasizes the crucial role of early breast cancer detection.

During a Case-Based Roundtable® event, Sagar D. Sardesai, MD, moderated a discussion on using antibody-drug conjugates and managing their toxicities in patients with metastatic breast cancer.